Akèy › Kasinòm nasofaringe
Etid klinik pou Kasinòm nasofaringe ap rekrite nan Etazini
13 etid pou Kasinòm nasofaringe ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Atlanta, GA6 etid
- Pittsburgh, PA3 etid
- Houston, TX3 etid
- Milwaukee, WI3 etid
- Oklahoma City, OK3 etid
- Cincinnati, OH3 etid
- Charlotte, NC3 etid
- Chicago, IL3 etid
- Washington, DC3 etid
- Los Angeles, CA3 etid
- San Francisco, CA3 etid
- Richmond, VA3 etid
Pa eta
- Georgia6 etid
- Illinois3 etid
- Kalifòni6 etid
- Maryland3 etid
- Missouri3 etid
- North Carolina3 etid
- Ohio3 etid
- Oklahoma3 etid
- Pennsylvania3 etid
- South Carolina3 etid
- Texas4 etid
- Virginia4 etid
- Wisconsin3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT06479811Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Ap rekriteFaz 2
Jiska laj 21 · Tout sèks · Mizajou Sep 14, 2026 · NCT06064097Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06532279A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT01365169Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT06592599Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT06682442Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 4, 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 11, 2026 · NCT06636734Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.